Top Page
Oncolytics Biotech
(NASDAQ:ONCY)
Oncolytics Biotech (ONCY) vs. SPDR S&P 500 ETF (SPY)
Oncolytics Biotech Business Overview & Revenue Model
Oncolytics Biotech Earnings Call Summary
Oncolytics Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -298.59K | -301.11K | -360.57K | -332.65K |
| EBITDA | -35.41M | -34.88M | -20.19M | -18.71M | -20.58M | -16.45M |
| Net Income | -35.27M | -31.71M | -20.56M | -19.08M | -20.98M | -16.78M |
Balance Sheet | ||||||
| Total Assets | 15.06M | 20.19M | 38.82M | 37.33M | 45.88M | 34.35M |
| Cash, Cash Equivalents and Short-Term Investments | 12.35M | 15.94M | 34.91M | 32.14M | 41.26M | 31.22M |
| Total Debt | 835.00K | 1.06M | 423.00K | 373.00K | 655.00K | 402.06K |
| Total Liabilities | 14.94M | 14.20M | 11.26M | 10.83M | 9.78M | 9.59M |
| Stockholders Equity | 115.00K | 5.98M | 27.56M | 26.50M | 36.10M | 24.75M |
Cash Flow | ||||||
| Free Cash Flow | -26.48M | -27.20M | -28.46M | -23.41M | -22.72M | -22.10M |
| Operating Cash Flow | -26.47M | -26.97M | -28.45M | -23.36M | -22.43M | -22.07M |
| Investing Cash Flow | -13.00K | -239.00K | 20.22M | -20.40M | -285.95K | -29.30K |
| Financing Cash Flow | 18.74M | 6.64M | 31.99M | 12.21M | 33.02M | 39.77M |
Oncolytics Biotech Risk Analysis
Oncolytics Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $130.15M | 3.47 | 24.38% | ― | ― | 814.20% | |
56 Neutral | $160.22M | -1.71 | -103.99% | ― | 250.00% | 15.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $107.72M | 7.96 | ― | ― | 51.27% | ― | |
49 Neutral | $174.85M | -1.36 | -49.18% | ― | -33.76% | 17.54% | |
45 Neutral | $85.91M | -2.78 | -48.89% | ― | ― | -9.42% | |
43 Neutral | $103.37M | -3.53 | -745.66% | ― | ― | ― |
Oncolytics Biotech Corporate Events
On November 20, 2025, Oncolytics Biotech announced the cancellation and rescheduling of its special meeting of shareholders initially planned for December 15, 2025. The decision was due to delays at the Securities and Exchange Commission caused by a recent U.S. federal government shutdown. The meeting, once rescheduled, will address a series of transactions, including the company’s proposed jurisdiction change from Alberta, Canada, to Nevada, USA. This move could significantly impact Oncolytics’ operational jurisdiction and strategic positioning.
The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
Oncolytics Biotech Inc. announced on November 19, 2025, that it has aligned with the FDA on the design of a pivotal Phase 3 study for pelareorep in combination with standard-of-care therapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). This trial, set to launch in the first half of 2026, will be the only current registration trial involving an immunotherapy for first-line pancreatic cancer, potentially offering a new treatment option where immunotherapies have shown limited benefits. The study will evaluate pelareorep with chemotherapy, with or without a checkpoint inhibitor, and aims to demonstrate a clinically meaningful survival benefit.
The most recent analyst rating on (ONCY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
On November 12, 2025, Oncolytics Biotech Inc. released its financial results for the three and nine months ended September 30, 2025. The company reported a net loss of $14.4 million for the third quarter, compared to $9.5 million in the same period last year. The increase in net loss was primarily due to higher general and administrative expenses. Despite the financial challenges, Oncolytics continues to focus on advancing its clinical programs, which are critical to its strategic positioning in the biotech industry.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
On November 4, 2025, Oncolytics Biotech announced the formation of a Gastrointestinal Tumor Scientific Advisory Board (SAB) to guide the clinical and regulatory strategy for pelareorep as a treatment for gastrointestinal cancers. The SAB, consisting of leading oncology experts, will play a crucial role in shaping the company’s GI oncology development strategy, including designing registration-enabling studies and exploring pathways for accelerated approval in select tumor types. This initiative is expected to strengthen Oncolytics’ position in the industry and potentially transform the treatment landscape for patients with GI tumors.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
On October 28, 2025, Oncolytics Biotech announced updated results from their GOBLET study, showing that the combination of pelareorep and atezolizumab achieved a 30% objective response rate in second-line or later squamous cell anal carcinoma (SCAC), more than doubling the current standard of care. The median duration of response was 15.5 months, significantly longer than the 9.5 months for existing treatments. These findings highlight pelareorep’s potential to drive durable tumor control and position Oncolytics for a possible accelerated approval study with the FDA in early 2026.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
On October 10, 2025, Oncolytics Biotech Inc. submitted a corporate presentation to the Securities and Exchange Commission, highlighting the potential of pelareorep as a transformative immunotherapy platform for gastrointestinal tumors. The presentation detailed the mechanism of action, safety profile, and clinical experience of pelareorep, which has shown promising results in various cancer indications. This development positions Oncolytics Biotech as a key player in the oncology sector, potentially impacting stakeholders by offering a novel treatment option for patients with GI tumors.
The most recent analyst rating on (ONCY) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.